Why the study?
New evidence published since the 2019 ESC/EAS Guidelines could influence clinical practice in the management of dyslipidaemias and required updated recommendations.
The 2025 ESC/EAS Focused Update incorporates recent trial data to revise recommendations on cardiovascular risk estimation, novel lipid-lowering therapies, and specific patient populations like those with ACS, HIV, or cancer.
Answers are grounded in this paper and cite their sources.
Revises lipid management for ACS, HIV, and statin-intolerant patients; extends 2019 ESC/EAS guidelines with post-2019 trial data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mach et al. (2025) conducted a review in Dyslipidaemia. Lipid-lowering therapies was evaluated. The 2025 ESC/EAS Focused Update provides revised recommendations for cardiovascular risk estimation, new LDL-C lowering therapies, and lipid management in specific populations.
Synapse has enriched 10 related papers. Consider them for comparative context: